125,408 Shares in REGENXBIO Inc. $RGNX Acquired by Los Angeles Capital Management LLC

Los Angeles Capital Management LLC acquired a new stake in shares of REGENXBIO Inc. (NASDAQ:RGNX) in the 2nd quarter, according to its most recent 13F filing with the SEC. The fund acquired 125,408 shares of the biotechnology company’s stock, valued at approximately $1,030,000.

Several other large investors have also made changes to their positions in the business. Acadian Asset Management LLC purchased a new position in shares of REGENXBIO during the first quarter worth $1,123,000. Invesco Ltd. grew its position in REGENXBIO by 52.4% during the 1st quarter. Invesco Ltd. now owns 79,469 shares of the biotechnology company’s stock worth $568,000 after purchasing an additional 27,341 shares during the period. Y Intercept Hong Kong Ltd purchased a new position in shares of REGENXBIO during the 2nd quarter valued at about $1,453,000. Cerity Partners LLC acquired a new position in shares of REGENXBIO in the 1st quarter valued at about $228,000. Finally, Charles Schwab Investment Management Inc. boosted its stake in shares of REGENXBIO by 4.8% in the first quarter. Charles Schwab Investment Management Inc. now owns 366,549 shares of the biotechnology company’s stock worth $2,621,000 after buying an additional 16,819 shares during the last quarter. 88.08% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at REGENXBIO

In related news, CEO Curran Simpson sold 20,811 shares of the company’s stock in a transaction dated Thursday, October 9th. The shares were sold at an average price of $12.62, for a total transaction of $262,634.82. Following the completion of the transaction, the chief executive officer owned 216,162 shares in the company, valued at $2,727,964.44. This represents a 8.78% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In the last three months, insiders have sold 36,169 shares of company stock worth $416,598. 12.79% of the stock is owned by corporate insiders.

REGENXBIO Stock Performance

REGENXBIO stock opened at $11.60 on Thursday. The company’s fifty day moving average price is $10.90 and its 200 day moving average price is $9.55. REGENXBIO Inc. has a 1 year low of $5.03 and a 1 year high of $13.93. The stock has a market capitalization of $587.19 million, a P/E ratio of -3.34 and a beta of 1.23.

REGENXBIO (NASDAQ:RGNX) last posted its quarterly earnings data on Thursday, November 6th. The biotechnology company reported ($1.20) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.38) by $0.18. The company had revenue of $29.73 million during the quarter, compared to analysts’ expectations of $24.41 million. REGENXBIO had a negative net margin of 110.29% and a negative return on equity of 78.29%. Sell-side analysts predict that REGENXBIO Inc. will post -4.84 EPS for the current year.

Analysts Set New Price Targets

Several research analysts recently weighed in on RGNX shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of REGENXBIO in a research report on Wednesday, October 8th. Barclays dropped their price objective on shares of REGENXBIO from $50.00 to $37.00 and set an “overweight” rating on the stock in a research note on Friday, August 8th. HC Wainwright reiterated a “buy” rating and issued a $34.00 target price on shares of REGENXBIO in a research note on Tuesday, October 7th. Royal Bank Of Canada raised their price target on shares of REGENXBIO from $17.00 to $19.00 and gave the company an “outperform” rating in a research report on Friday, November 7th. Finally, Wall Street Zen raised shares of REGENXBIO from a “sell” rating to a “hold” rating in a report on Saturday, November 8th. Five investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $28.63.

REGENXBIO Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.